Genexine EBIT per Share
The EBIT per Share of Genexine (095700.KQ) as of Oct 18, 2026 is -793.17 KRW. In the previous year, EBIT per Share was -1,403.66 KRW — a change of -43.49% (higher).
Get this data via API
Financial Data API
EBIT per Share
-793.17KRW
YoY
-43.49%
Last updated:
The Genexine EBIT per Share history
3 Years
10 Years
25 Years
Max
| YEAR | EBIT per Share | YoY |
|---|---|---|
| est | -515.27KRW | -159.48% |
| est | 866.28KRW | -166.96% |
| est | -1,293.71KRW | +4,315.43% |
| est | -29.30KRW | -96.83% |
| est | -924.04KRW | +116.71% |
| est | -426.39KRW | -46.24% |
| -793.17KRW | -43.49% | |
| -1,403.66KRW | -9.48% | |
| -1,550.72KRW | +50.51% | |
| -1,030.32KRW | +86.19% | |
| -553.37KRW | -65.09% | |
| -1,585.22KRW | -15.43% | |
| -1,874.53KRW | +38.40% | |
| -1,354.43KRW | +39.38% | |
| -971.75KRW | -22.88% | |
| -1,260.05KRW | +18,518.29% | |
| -6.77KRW | -98.18% | |
| -371.93KRW | -36.69% | |
| -587.50KRW | +31.34% | |
| -447.33KRW | -59.28% | |
| -1,098.57KRW | -6.81% | |
| -1,178.86KRW | +1,391.47% | |
| -79.04KRW | +22.54% | |
| -64.50KRW | +251.82% | |
| -18.33KRW | -175.86% | |
| 24.17KRW | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Genexine Stock analysis
Frequently Asked Questions about Genexine stock
EBIT per Share of Genexine is -793.17 KRW in 2025.
EBIT per Share of Genexine changed from -1,403.66 KRW to -793.17 KRW, representing a -43.49% change. The value is higher than the previous year.
On Eulerpool you can find the complete historical development of EBIT per Share Genexine since 2006 – with annual values, charts, and detailed analysis.
EBIT per Share measures operating profit allocated to each outstanding share.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Income Statement — Genexine
All Key Metrics — Genexine
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth